Celgene International Sárl (CELG) Release: Study Evaluating REVLIMID® Combination Compared to Autologous Stem Cell Transplant with or without REVLIMID Maintenance in Newly-Diagnosed Multiple Myeloma Presented at American Society of Clinical Oncology
6/3/2013 7:59:00 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced data from a study comparing melphalan, prednisone and REVLIMID (lenalidomide) (MPR) with high-dose chemotherapy and tandem autologous stem cell transplant (MEL200), as well as evaluating the effect of lenalidomide maintenance in patients with newly-diagnosed multiple myeloma were presented during a June 3rd oral session at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting in Chicago, Ill.
Help employers find you! Check out all the jobs and post your resume.
comments powered by